腸内微生物群と血液形成幹細胞移植後の結果への影響:包括的なレビュー
PubMedで要約を見る
まとめ
この要約は機械生成です。腸内微生物群の操作は,血液形成幹細胞移植 (HSCT) を受けている患者の結果を改善することができます. 有益な微生物を回復させることで 移植対宿主疾患や感染症などの合併症を軽減し 患者の生存率を高めることができます
科学分野
- 微生物群の研究
- 血液形成幹細胞移植 (HSCT)
- 免疫学
背景
- 血液形成性幹細胞移植 (HSCT) は,血液学的癌の治療に不可欠ですが,移植対宿主疾患,感染,再発などの重大なリスクがあります.
- 微生物の多様性の減少と病原体の膨張によって特徴づけられる微生物不活性症は,HSCT後の有害な結果と死亡率とますます関連しています.
- 腸内微生物群が 移植の成功に及ぼす影響は 治療的介入の探索を 必要としています
研究 の 目的
- HSCTの結果における微生物群の役割を検討する.
- HSCTの合併症を緩和するためのマイクロバイオーム操作戦略を探求する.
- HSCTによる癌治療における 微生物工学の可能性を議論する.
主な方法
- HSCTに対する微生物群の影響に関する最近の科学的証拠と実験的発見のレビュー
- プロバイオティクス,プレバイオティクス,糞便の微生物群移植,食事介入を含む微生物群操作アプローチの分析
- マイクロバイオームベースのHSCT療法における課題と将来の研究方向の検討
主要な成果
- HSCT後の合併症および死亡率の増加と関連しています.
- 有益な微生物の回復は,免疫を強化し,移植対宿主疾患の重症度を軽減し,感染率を下げる可能性を示しています.
- 微生物群の操作は 移植の成果を向上させる 有望な手段です
結論
- 腸内微生物コミュニティを微生物工学で最適化することで,HSCT受容者の生存と生活の質を向上させる大きな可能性があります.
- プロトコル標準化,長期的な有効性,免疫低下患者の安全性などの課題に対処するためにさらなる研究が必要である.
- マイクロバイオームベースの治療は,HSCTの文脈で癌の治療に革命的なアプローチを表しています.
関連する概念動画
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
Tissue transplantation is a significant medical procedure involving the transfer of cells, tissues, or organs from a donor to a recipient, with the primary aim of restoring lost functions. This procedure is crucial in treating a broad spectrum of diseases, including kidney diseases, liver failure, heart disease, and certain types of cancers.
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...
Hematopoiesis, or blood cell production, is a vital biological process that begins early in embryonic development and continues throughout life. This process generates the various types of cells found in blood, including red blood cells, white blood cells, and platelets from hematopoietic stem cells (HSCs).
Developmental Phases of Hematopoiesis
Initially, HSCs are formed in the embryonic yolk sac, a critical site for early blood cell production. These stem cells subsequently migrate to other...
Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...

